GlassScriptPhysician profile
Alexander Bagasra
NPI 1083871800
$5,446.94
in general payments reported to CMS, 2019-2025
26 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 80% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $283 · 2021: $768 · 2022: $903 · 2023: $787 · 2024: $771 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,429 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,429.44 |
| Education | $201.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $1,076.03 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Viiv Healthcare Company | $751.96 | 2019-2024 | Dovato, Apretude, Rukobia |
| Insmed, INC. | $568.51 | 2019-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $485.11 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $460.27 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Shionogi INC | $455.19 | 2021-2025 | Fetroja |
| Abbvie INC. | $352.32 | 2021-2025 | Avycaz, Teflaro, Mavyret |
| Janssen Biotech, INC. | $186.14 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $179.46 | 2019-2023 | Egrifta Sv, Egrifta, Trogarzo |
| La Jolla Pharmaceutical Company | $165.73 | 2022-2025 | Xerava, Xacduro |
| Paratek Pharmaceuticals, INC. | $138.50 | 2019-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $114.32 | 2021-2025 | Cuvitru |
| Janssen Pharmaceuticals, INC | $81.21 | 2022 | |
| Janssen Products, LP | $54.99 | 2022 | |
| Astellas Pharma US INC | $52.93 | 2024-2025 | Cresemba |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $51.72 | 2023 | |
| Pfizer INC. | $47.89 | 2023-2025 | |
| Napo Pharmaceuticals INC | $34.81 | 2025 | Mytesi |
| Allergan, INC. | $31.88 | 2019-2020 | |
| Dynavax Technologies Corporation | $29.59 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $28.97 | 2022 | |
| Smith+Nephew, INC. | $24.78 | 2021 | |
| Vyera Pharmaceuticals, LLC | $22.35 | 2022 | |
| Pharming Healthcare, INC. | $21.62 | 2024 | Ruconest |
| Janssen Scientific Affairs, LLC | $17.04 | 2021 | |
| Tactile Systems Technology INC | $13.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Bagasra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.